News
Apogenix’s asunercept demonstrates efficacy in COVID-19 trial
Apogenix’s asunercept treatment has shown statistically significant benefits for hospitalised COVID-19 patients in its Asunctis trial.
You're using an outdated browser. To get the most out of this website, as well as many others, please consider upgrading to a modern browser, such as Google Chrome, Mozilla Firefox, or Microsoft Edge.
Apogenix’s asunercept treatment has shown statistically significant benefits for hospitalised COVID-19 patients in its Asunctis trial.